Despite J&J's Rybrevant full nod, FDA encourages Dizal to file rival lung cancer drug for accelerated approval
Despite J&J's Rybrevant full nod, FDA encourages Dizal to file rival lung cancer drug for accelerated approval
aliu
СМИ24.net — правдивые новости, непрерывно 24/7 на русском языке с ежеминутным обновлением *
